What's happening? Current status of high dose chemotherapy in breast cancer

Stefan Glück, Douglas Stewart

Research output: Contribution to journalShort surveypeer-review


To date, no definite answers are available to the initial question, as to whether or not HDCT and ASCT can improve the quantity or quality of life. Completing the available prospective, randomized phase III studies; using HDCT earlier in the course of treatment, applying drugs that are active against breast cancer, comparing the experimental treatment to standard therapy, and using appropriate sample size to detect clinically meaningful and statistically significant differences are all paramount requirements to answer the question successfully. Within the next few years, a number of European [13] and two Canadian studies [6, 14] that are currently accruing patients, will contribute important information regarding the role of HDCT and ABMT for breast cancer.

Original languageEnglish (US)
Pages (from-to)211-214
Number of pages4
JournalTransfusion Science
Issue number3
StatePublished - Dec 1999

ASJC Scopus subject areas

  • Immunology
  • Hematology


Dive into the research topics of 'What's happening? Current status of high dose chemotherapy in breast cancer'. Together they form a unique fingerprint.

Cite this